reported Sunday.” data-reactid=”19″>CanSino Biologics Inc (OTC: CASBF) has become the first company to secure a patent for its COVID-19 vaccine in China, Reuters reported Sunday.
What Happened
The Tianjin, China-based company’s patent for its Ad5-nCOV vaccine against COVID-19 stands approved by China’s National Intellectual Property Administration as of August 11, according to Reuters.
Saudi Arabia announced last month plans to test the CanSino vaccine in Phase 3 trials. The company is reportedly also negotiating with Brazil, Chile, and Russia to launch similar trials.
Why It Matters
approved by Canadian federal health regulator. ” data-reactid=”28″>In May, the Chinese vaccine maker’s Phase 2 clinical trial application was approved by Canadian federal health regulator.
PFE) and its partner BioNTech SE (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA), Johnson and Johnson (NYSE: JNJ) are in late-stage trials or nearing them.
NVAX) vaccine in a supply deal reached with the company.
AZN) has inked a deal with the governments of Mexico and Argentina for supply of its potential COVID-19 vaccine to Latin American countries, excluding Brazil.
Russia claims its “Sputnik V” vaccine is available for immediate use, but the absence of a Phase 3 trial is leading to a division among experts on safety.
Price Action
CanSino OTC shares closed nearly 2.6% lower at $25.36 on Friday.
View Article Origin Here
